Cannabis Law Report

AUGUST 18, 2022

Among the first in the nation, Phillips Lytle’s Psychedelics Practice Team combines expertise in pharmaceutical science, FDA regulations and risk management to serve the legal needs of emerging bio-tech sectors. Promising research in psychedelics as a mental health treatment accelerates growth of industry in need of legal counsel.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Veriheal

JUNE 7, 2021

Note: Veriheal does not support illegally consuming therapeutic substances like MDMA but acknowledges that it transpires because of the current illicit status of both, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting alternative therapies.

Therapy 92

Therapy Treatment Conditions Clinical Trials 92

Cannabis Law Report

MAY 19, 2022

” Hartle, 54, is one of the very few Canadians to have received legal psychedelics psychotherapy for a mental health condition since Health Canada made it easier in January for health-care workers to access psilocybin — the hallucinogenic compound found in some mushrooms. .” It’s just you and the music.”

Therapy 52

Therapy Patients Treatment Clinical Trials 52

Cannabis Law Report

MAY 31, 2022

The short answer is: that current legal options (i.e. legal at the state level or the state and federal level) are limited. The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Federal Legal Status.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

APRIL 27, 2022

A Colorado Senate committee on Wednesday unanimously approved a House-passed bill to align state statute to legalize MDMA prescriptions if and when the federal government ultimately permits such use. The MDMA legislation , meanwhile, would legalize “prescribing, dispensing, transporting, possessing, and using” MDMA if the U.S.

Clinical Trials 52

Clinical Trials Legalization Therapy Food 52

SpeedWeed

MAY 22, 2021

The US Food and Drug Administration (FDA) has just approved a new clinical trial that will allow therapists to legally use MDMA. For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. .

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

Veriheal

MARCH 20, 2023

Alternative medicine is becoming more widely acknowledged and practiced than ever before, opening the door for therapies like psychedelics to enter the world of mainstream healthcare. Psilocybin therapy is both studied and used by highly legitimate medical establishments. Ned Lamont signed a bill (HB 5506) to fund psychedelic therapy.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

Cannabis Law Report

MAY 28, 2022

Natasha Sumner, Kimberly Chew and Karen Luong are attorneys in Husch Blackwell LLP’s virtual office, The Link, and lead the firm’s Psychedelics & Emerging Therapies practice. Husch Blackwell is the first Am Law 100 firm to establish a Psychedelics and Emerging Therapies practice group. How did this come to fruition?

Research and Development 52

Research and Development Therapy Clinical Trials Legalization 52

Cannabis Law Report

JUNE 24, 2022

The leader of the New Jersey Senate filed a bill on Thursday that would legalize the possession, home cultivation and gifting of psilocybin mushrooms for adults 21 and older—with provisions that give adults even more freedoms for the psychedelic than are afforded under the state’s current marijuana laws. Marijuana Moment reports.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

CannaMD

AUGUST 26, 2020

A new review published by scientific journal, Pharmacology Biochemistry and Behavior , has found that marijuana cannabinoid, CBD, is a “promising” therapy for treating cocaine dependence. Exploring alternative therapies, researchers turned their attention to marijuana cannabinoid, cannabidiol – more commonly referred to as CBD.

Therapy 98

Therapy CBD Research and Development Treatment 98

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

AUGUST 7, 2021

We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Key Responsibilities.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. MEDIA CONTACT .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

NewsMunchies

NOVEMBER 12, 2021

As the cannabis industry continues to grow and evolve with legalization achieved in many parts of the world, we’re seeing an increase in activity related to another substance that will hopefully be removed from the list of controlled substances – psilocybin. As such, magic mushroom therapy offers hope. Let’s put science first.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. This Essay analyzes the ethical, legal, and social implications of patenting these controversial substances. 11 × 11. In 2017, the FDA designated MDMA a breakthrough therapy for PTSD. 10 × 10.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. Exploring CBD for Medical Use As interest in CBD grows, researchers are continuously exploring its potential applications in the medical field.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

NOVEMBER 1, 2021

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. This Essay analyzes the ethical, legal, and social implications of patenting these controversial substances. Glenn, Patents on Psychedelics: The Next Legal Battlefront of Drug Development (October 23, 2021).

Research and Development 52

Research and Development Law Clinical Trials Therapy 52

Cannabis Law Report

AUGUST 30, 2021

‘Psychedelic renaissance’ sees first legal collection of Australia’s medicinal magic mushrooms. Key points: This will be Australia’s first legal collection of magic mushrooms. It’s considered a breakthrough therapy,” Dr McTaggart said. The ABC reports. Supplied: Dr Alistair McTaggart. ).

Clinical Trials 105

Clinical Trials Collective Therapy Treatment 105

Cannabis Law Report

JULY 9, 2021

This article provides an overview of the current state of legality of common psychedelic substances, and some of the potential therapeutic uses to which psychedelics may be applied. The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.”

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

JULY 24, 2021

“The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Canna Law Blog

JANUARY 22, 2020

The company is also running a phase IIb clinical trial of its patented formulation, COMP360, which we covered in a blog post back in 2018. In that post, I explained how the Food and Drug Administration (FDA) approval process works and why this trial is so interesting and important. Psilocybin!

Clinical Trials 116

Clinical Trials Decriminalization Microdosing Food 116

Cannabis Law Report

OCTOBER 2, 2021

We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

JUNE 29, 2021

Synergetic Press and the Multidisciplinary Association for Psychedelic Science (MAPS) are pleased to announce they have entered into a copublishing relationship effective May 1, 2021 which will greatly expand the availability of education about psychedelics and psychedelic therapy.

Therapy 90

Therapy Research and Development Clinical Trials Education 90

CannaMD

JUNE 2, 2021

Responses came from 49 states, of which 15 had not currently legalized medical marijuana at the time of the study. Of those states that had legalized medical marijuana, 14 currently consider Parkinson’s disease a qualifying condition for medical marijuana therapies. Florida is among these states. Find Out if You Qualify.

Patients 105

Patients Clinical Trials Treatment Research and Development 105

Canna Care Docs

OCTOBER 3, 2023

Natural plant therapy , and cannabis specifically, has been studied for its effectiveness in alleviating and treating many of these physiological and emotional symptoms that come into play with a terminal illness. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Veriheal

MAY 26, 2022

With new and improved products popping up left and right, legalization initiatives taking off all over the globe, and harmful “stoner” stigmas quickly dissipating, it’s clear that cannabis has entered a new era. The days of “reefer madness” are long over, replaced by a growing acknowledgment of the cannabis plant’s therapeutic abilities.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Cannabis Law Report

MAY 29, 2022

In 2020, Oregon became the first locale to decriminalize psilocybin and legalize it for therapeutic use on a statewide basis. FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

SpeedWeed

JULY 6, 2021

Harvard Law School is planning to open the first US policy center focused on the legalization and regulation of psychedelics like psilocybin, MDMA, and LSD. . By analyzing social, legal, and political barriers to access in this context, we hope to advance the understanding of their potential impact as therapeutics.”.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

DECEMBER 9, 2021

“We believe it is the responsibility of psychedelic-therapy companies to provide material support to the life-changing research being done in the space, which has made our work possible. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

MARCH 12, 2020

KEY FINDINGS FROM THE REPORT INCLUDE: While cannabis has already paved much of the way for psychedelics in terms of legal progress and changing public perception, psychedelics as medicines are already backed by a more powerful knowledge base comparatively. Unsurprisingly the event follows in June.

Medicine 59

Medicine Clinical Trials Therapy Events 59

Cannabis Law Report

AUGUST 25, 2021

Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

JULY 1, 2021

The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. While psychedelic therapies make their way through the drug development pipeline, seven U.S.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

APRIL 2, 2022

Dr. Rasmussen is a pioneer and one of the leading names in psychedelic medicine in Brazil where ketamine and ibogaine are legal for medical use in psychotherapies. We are pleased to contribute our clinical expertise and renowned therapy protocols to help achieve this vision.” ” About Novamind.

Clinical Trials 52

Clinical Trials Research and Development Medicine Therapy 52

PrestoDoctor

OCTOBER 11, 2023

However, with the increasing legalization and the growing awareness of its health benefits, there has been a shift in perception. In recent years, there has been growing interest in exploring alternative therapies for individuals with ASD. This is typically below the legal limit of 0.3%.

CBD 52

CBD Research and Development Clinical Trials Treatment 52

CannaMD

MAY 12, 2021

It’s well known that marijuana can be an agent for appetite stimulation, making it a valuable therapy for mitigating the weight loss sometimes associated with conditions such as HIV/AIDS and cancer. It therefore stands to reason that therapies addressing anxiety and OCD might have a positive effect on eating disorders.

Marijuana 119

Marijuana Therapy Conditions Food 119